Rotator cuff tears (RCTs) are among the most common shoulder disorders, and they have a significant impact on patients. For example, RCTs substantially reduce patients' quality of life. In 2002, rotator cuff disorders accounted for more than 4.5 million physician visits and approximately 40,000 inpatient procedures in the United States.^[@bibr20-2325967118782159]^ The common symptoms of RCTs include intense pain, difficulty in getting to sleep and staying asleep, and restrictions in ability and mobility.^[@bibr17-2325967118782159]^ These symptoms usually have a significant impact on patients' activities of daily living, leisure activities, occupation, and emotional state.^[@bibr17-2325967118782159]^ Therefore, to assess the severity of RCTs and evaluate the effectiveness of different treatment options, we need valid and reliable instruments and appropriate criteria to measure the patient's perceived and self-reported symptoms.

The Veterans RAND 12-Item Health Survey (VR-12) and the Single Assessment Numeric Evaluation (SANE) are 2 patient-reported outcome measures (PROMs) used to evaluate the impact of RCTs on life quality and shoulder function.^[@bibr6-2325967118782159],[@bibr9-2325967118782159],[@bibr22-2325967118782159]^ The VR-12 is developed from the SF-36 (36-Item Short Form Health Survey) and is used to assess health-related quality of life and estimate disease burden.^[@bibr9-2325967118782159]^ The SANE score is a single numeric self-evaluation of shoulder function.^[@bibr6-2325967118782159]^ These 2 PROMs enable clinicians and researchers to interpret and integrate patients' opinions in clinical decision making when treating patients with RCT.

One challenge in interpreting the results of the PROMs is to determine whether a detected change in the score is sufficient to warrant a change in treatment.^[@bibr21-2325967118782159]^ A statistically significant difference does not necessarily represent a meaningful change for the patients and clinicians, who are usually more interested in the clinical relevance of the detected differences.^[@bibr21-2325967118782159]^ To determine how much change is enough to be considered important to patients, the minimal important difference (MID) analysis was developed to assist in the interpretation of PROMs among other types of outcome measures. MID is defined as "the smallest difference in scores of a PROM that is perceived by patients as beneficial or harmful, which would lead the clinician to consider a change in treatment."^[@bibr21-2325967118782159]^ It provides us with evidence on the effects of a treatment perceived by patients and assists health care professionals with improving the effectiveness of health care services. Previous studies have suggested that the MID may vary across populations and treatments.^[@bibr1-2325967118782159],[@bibr21-2325967118782159],[@bibr23-2325967118782159]^ It is rarely appropriate to apply a single MID for all patient populations, and multivariate adjustment of baseline characteristics has been used to help reduce the bias.^[@bibr2-2325967118782159],[@bibr3-2325967118782159],[@bibr4-2325967118782159],[@bibr16-2325967118782159]^ Therefore, to use MIDs in clinical and research settings to assess the perceived changes of patients with RCT, we need to establish the MID estimates in a representative study sample of patients with RCT.

Anchor-based and distribution-based methods are commonly used to estimate the MID.^[@bibr21-2325967118782159]^ The anchor-based approaches apply patient-based or clinician-based variables as anchors to determine the change in health status in the target population and examine the relationship between the anchor and the PROM being investigated.^[@bibr21-2325967118782159]^ To determine the MID for a PROM, the anchor-based approach uses an anchor to identify the patients who perceive a MID after receiving the treatment and then to calculate in the change in the PROM scores of those patients. For example, in our study, we used a global health questionnaire as the anchor to quantify the difference in VR-12 scores between baseline and 64 weeks. In the global health questionnaire, the patients were asked to evaluate their changes in overall health using a 5-point scale. We first specified that a score of 2 or 3 on the global health questionnaire represented a minimal important change of health for the patients. Then, using this external criterion (anchor), we could identify the patients who perceived a minimal important change in their overall health after the treatments. Therefore, the mean change in the VR-12 score of those patients was the MID for the VR-12 score. The distribution-based approaches use statistical measures of the distribution of the PROM scores to estimate the MID and do not directly indicate the clinical relevance of the change.^[@bibr11-2325967118782159],[@bibr21-2325967118782159]^ To achieve a better estimation, studies have suggested using multiple approaches to estimate the MID for a PROM.^[@bibr11-2325967118782159],[@bibr21-2325967118782159]^

To our knowledge, although VR-12 and SANE are widely used in patients with RCT, no study exists that investigates the MIDs for these measures in patients following treatment for RCT. Therefore, the primary objective of this study was to establish MIDs for the VR-12 score and SANE rating using both anchor- and distribution-based techniques in patients with RCT. Our secondary objective was to examine factors that can predict variations in the MIDs.

Methods {#section1-2325967118782159}
=======

Study Design {#section2-2325967118782159}
------------

After approval by our internal review board, we used data from a prospective cohort study including 222 patients. In the distribution-based approach, the VR-12 and SANE scores of all the patients were used to determine the final MIDs. In MID analysis using the anchor-based approach, according to the results of the global health questionnaire, we included 21 patients who indicated only a minimal important improvement (patients with no, moderate, or large improvements were excluded from this analysis).

Population {#section3-2325967118782159}
----------

The participants in our study were adults seeking treatment for RCTs. The criteria for study inclusion were as follows: (1) adult patient (≥18 years old); (2) unilateral RCT of any size diagnosed by use of magnetic resonance imaging or diagnostic musculoskeletal ultrasonography; (3) first-time RCT in the affected shoulder; (4) signed informed consent; and (5) availability for 12-month follow-up. Exclusion criteria were history of surgery, infection, fracture, dislocation, and open repair of the affected shoulder.

To recruit participants, clinicians identified patients experiencing RCT. Included patients needed to sign an informed consent document and fill out multiple questionnaires.

Intervention {#section4-2325967118782159}
------------

The study patients were treated by 3 shoulder surgeons. Operative or nonoperative treatments were assigned to a patient based on the agreement of the patient and his or her physician.

Data Collection {#section5-2325967118782159}
---------------

Initially, each participant received a paper copy of the questionnaire to complete. Our clinical research coordinator was available to assist patients who had questions. The following information was collected: demographic information, smoking status, duration of symptoms, tear size, tear location, time since injury, cause of injury, medical history, physical examination results, surgical or nonsurgical treatment, and the Charlson Comorbidity Index (CCI). The CCI is commonly used to categorize comorbidities of patients based on the International Classification of Diseases diagnostic codes.^[@bibr18-2325967118782159]^ Patients with a higher CCI score have a higher risk of mortality or more use of health care resources.^[@bibr18-2325967118782159]^ Outcome measure follow-ups were conducted at 64 weeks postoperatively. The follow-up questionnaire contained VR-12, SANE, and a global rating of change question.

Outcome Measures {#section6-2325967118782159}
----------------

Our outcome measures included the VR-12, the SANE rating, and a global rating of change questionnaire.

The VR-12 is one of the most commonly used health-related quality of life instruments. It consists of 12 items corresponding to 8 principal domains, including general health perception, physical functioning, role limitations due to physical and emotional problems, bodily pain, energy-fatigue, social functioning, and mental health.^[@bibr9-2325967118782159]^ A physical component score (PCS) and a mental component score (MCS) are generated through summarizing the 12 items that measure physical and mental health status.^[@bibr9-2325967118782159]^

The SANE rating is commonly used by North American surgeons to evaluate patients' satisfaction with their shoulder function and is easy to administer.^[@bibr6-2325967118782159]^ It has only 1 question: "How would you rate your shoulder today as a percentage of normal?"^[@bibr6-2325967118782159]^ The patients need to provide their responses as a numeric percentage from 0 to 100.

The global change questionnaire was given to the participants at the 64-week follow-up to identify those who perceived a minimal important change. The patients were first asked whether after the treatment, they felt better, worse, or the same; then they were asked to quantify their change on a 5-point ordinal rating scale, with 5 representing a "great deal different." We only considered the patients giving a rating of 2 or 3 points as having a MID.^[@bibr10-2325967118782159]^

Distribution-Based Approach {#section7-2325967118782159}
---------------------------

A distribution-based approach is used to estimate MID based on the distribution statistics of observed PROM scores from study samples.^[@bibr21-2325967118782159]^ Various distribution-based methods have been used, such as SD and effect size. Our study applied the 1/2 standard deviation (SD) of the baseline PROM score to approximate the MID, as it was suggested to be meaningful to the patients.^[@bibr19-2325967118782159],[@bibr21-2325967118782159]^ For each PROM score, we divided the SDs of their baseline scores by 2 and used the results as our distribution-based MID estimations. Because only the baseline PROM scores are needed during this process, all the study participants with a baseline VR-12 or SANE score were included in the analysis.

Anchor-Based Approach {#section8-2325967118782159}
---------------------

Estimation of the anchor-based MIDs requires the baseline scores, global health ratings (anchor), and final PROM scores. In addition, since the anchor-based MIDs are the score changes for only the patients with a minimal important improvement, we conducted the analysis based on the information of the patients from the minimal important change group. This group included the patients who indicated a better overall health condition and gave a rating of 2 or 3 on the ordinal scale of the global health questionnaire.

For each PROM, we first identified all the patients in the minimal important group and subtracted their baseline score from the 64-week score to compute the individual MIDs, which were the differences between baseline and final scores. We then calculated the means of the individual MIDs. In the regression analysis, we used the individual MID as an outcome to study the associations between patients' baseline characteristics and the MID.

Statistical Analysis {#section9-2325967118782159}
--------------------

We examined the demographic, treatment, and comorbidity characteristics of included patients. Paired *t* test was used to examine whether the mean changes in the VR-12 PCS, the VR-12 MCS, and the SANE from baseline to 64 weeks among the minimal improvement group were statistically significant. Then, we used simple linear regression to investigate the association between each patient's demographic, treatment, and comorbidity characteristics and the anchor-based MIDs. The response variable was the MID for each participant, and the predictor variables included age, sex, body mass index (BMI), CCI scores, baseline PROM scores, diabetes, smoking status, side of injury, symptom duration, treatment type, and tear size. In addition, to build a model that could adequately predict the MID of the VR-12 and SANE with few variables, we used backward model selection. The first step in the backward model selection process was a multivariable analysis with independent variables that were significantly associated with the outcome in simple linear regressions. From the results of simple linear regressions for each of the MIDs, the 6 variables with the lowest *P* value were chosen as candidate variables in this step. We then eliminated the variables that were not significantly associated with the outcome after controlling for other variables. Finally, we reached a regression model with only variables that were associated with the outcome after adjusting for the effects of other covariates. The criterion used for the model selection was *P* value less than .10. All the analyses were performed using SAS 9.4 software (SAS Institute).

Results {#section10-2325967118782159}
=======

The demographic and clinical characteristics of the participants are presented in [Table 1](#table1-2325967118782159){ref-type="table"}. A total of 222 patients with full-thickness RCTs were recruited and completed the baseline assessments. Among those patients, 133 (59.9%) were males and 89 (40.1%) were females. Their average age was 60.5 years (90% CI, 59.4-61.5 years). The mean BMI was 30.25 kg/m^2^ (90% CI, 29.6-30.9 kg/m^2^). A total of 127 patients (57.2%) received surgical treatment and 95 (42.8%) received nonsurgical treatments. Mean baseline VR-12 PCS score was 38.0 (90% CI, 36.9-39.1), and mean baseline MCS score was 50.0 (90% CI, 48.7-51.3). Mean baseline SANE score was 28.3 (90% CI, 25.7-31.0).

###### 

Demographic and Baseline Characteristics^*a*^

![](10.1177_2325967118782159-table1)

                     Distribution-Based Analysis^*b*^   Anchor-Based Analysis^*c*^                                
  ------------------ ---------------------------------- ---------------------------- --------------- ---- ------- ---------------
  Total              222                                \-                           \-              21   \-      \-
  Age                222                                \-                           60.45 (9.62)    21   \-      63.05 (9.49)
  BMI                222                                \-                           30.25 (6.15)    21   \-      31.23 (5.47)
  CCI                217                                \-                           0.23 (0.82)     20   \-      0.15 (0.49)
  Baseline PCS       222                                \-                           38.01 (9.89)    21   \-      39.24 (11.26)
  Baseline MCS       222                                \-                           49.99 (11.97)   21   \-      50.73 (10.86)
  Baseline SANE      213                                \-                           28.34 (23.60)   21   \-      24.62 (16.08)
  Sex                                                                                                             
   Male              133                                59.91                        \-              14   66.67   \-
   Female            89                                 40.09                        \-              7    33.33   \-
  Smoke                                                                                                           
   Yes               28                                 12.61                        \-              4    19.05   \-
   No                194                                87.39                        \-              17   80.95   \-
  Diabetes                                                                                                        
   Yes               30                                 13.51                        \-              3    14.29   \-
   No                192                                86.49                        \-              18   85.71   \-
  Injection                                                                                                       
   Yes               87                                 39.19                        \-              8    38.10   \-
   No                135                                60.81                        \-              13   61.90   \-
  Surgery                                                                                                         
   Yes               127                                57.21                        \-              6    28.57   \-
   No                95                                 42.79                        \-              15   71.43   \-
  Tear size                                                                                                       
   Missing           2                                  0.90                         \-              \-   \-      \-
   Small/medium      159                                71.62                        \-              12   57.14   \-
   Large/massive     61                                 27.48                        \-              9    42.86   \-
  Side                                                                                                            
   Right             135                                60.81                        \-              13   61.90   \-
   Left              87                                 39.19                        \-              8    38.10   \-
  Symptom duration                                                                   \-                           \-
   ≤1 year           154                                69.37                        \-              12   57.14   \-
   \>1 year          68                                 30.63                        \-              9    42.86   \-

^*a*^ BMI, body mass index; CCI, Charlson Comorbidity Index; MCS, mental component score; PCS, physical component score; SANE, Single Assessment Numeric Evaluation.

^*b*^ All 222 patients who participated in the study were included in estimating the distribution-based minimal important difference (MID).

^*c*^ The anchor-based MIDs were estimated using information from 21 patients who indicated a minimal important improvement.

Of the 222 patients, 160 (72.1%) completed the 64-week assessment and evaluated their improvement in health status using a global rating of change questionnaire. Twenty-one patients indicated a minimal improvement according to the global rating questionnaire. Among the participants in the minimal improvement group, 20 participants finished the 64-week VR-12 and SANE. For the participants who did not complete the 64-week questionnaire, the reasons were death, dropout, and unknown.

Distribution-Based Analysis {#section11-2325967118782159}
---------------------------

The MIDs estimated using the distribution-based method can be found in the [Table 2](#table2-2325967118782159){ref-type="table"}. The 1/2 SD--based MID estimates for the PCS, MCS, and SANE score were 4.94, 5.99, and 11.80, respectively.

###### 

VR-12 (MCS and PCS) Minimal Important Difference (MID)^*a*^

![](10.1177_2325967118782159-table2)

                                    n        Mean    SD      90% CI (lower bound)   90% CI (upper bound)   *P* Value^*b*^ (*t* test)
  --------------------------------- -------- ------- ------- ---------------------- ---------------------- ---------------------------
  Anchor-based MID                                                                                         
   PCS                              20.00    2.57    10.84   −1.62                  6.76                   .303
   MCS                              20.00    1.87    10.18   −2.07                  5.80                   .422
   SANE                             20.00    27.25   28.65   16.17                  38.33                  \<.001
  Distribution-based MID (1/2 SD)                                                                          
   PCS                              222.00   4.94            \-                     \-                     \-
   MCS                              222.00   5.99            \-                     \-                     \-
   SANE                             213.00   11.80           \-                     \-                     \-

^*a*^ MCS, mental component score; PCS, physical component score; SANE, Single Assessment Numeric Evaluation; VR-12, Veterans RAND 12-Item Health Survey.

^*b*^ *P* values were from the *t* test comparing the 64-week score to the baseline score.

Anchor-Based Analysis {#section12-2325967118782159}
---------------------

The mean MIDs between baseline and 64 weeks were 2.57 for the PCS, 1.87 for the MCS, and 27.25 for the SANE score ([Table 2](#table2-2325967118782159){ref-type="table"}). The results of the paired *t* tests showed no statistically significant difference in the MCS and PCS scores between baseline and 64 weeks posttreatment. However, the difference between the baseline and 64-week SANE scores was statistically significant (*P \<* .001).

In the simple linear regressions with the MID of PCS as the dependent/response variable, baseline PCS and symptom duration showed negative significant associations with the MID ([Table 3](#table3-2325967118782159){ref-type="table"}), indicating that the MID decreased as baseline score or symptom duration increased. The results of the simple linear regressions for the MID of MCS indicated 3 significant negative associations: baseline MCS, female sex, and no diabetes ([Table 4](#table4-2325967118782159){ref-type="table"}). In the simple linear regression analyses for the MID of SANE ratings, only diabetes and the baseline SANE score were significantly negatively associated with the MID.

###### 

Simple Linear Regression Analyses for VR-12 (MCS and PCS) Anchor-Based MID*^a^*

![](10.1177_2325967118782159-table3)

                                PCS      MCS                                                    
  ----------------------------- -------- ----------------- ----------- ------- ---------------- -----------
  Age                           \<0.00   −0.46 to 0.45     .995        −0.20   −0.62 to 0.22    .411
  BMI                           −0.53    −1.31 to 0.25     .252        −0.06   −0.81 to 0.70    .895
  Baseline score                −0.55    −0.86 to −0.23    .007^*b*^   −0.58   −0.87 to −0.30   .003^*b*^
  CCI                           −4.62    −13.47 to 4.24    .377        −1.27   −10.03 to 7.48   .803
  Sex                                                                                           
   (ref = female)               −0.35    −9.77 to 9.07     .950        9.97    2.11 to 17.82    .041^*b*^
  Injection                                                                                     
   (ref = no injection)         4.14     −4.51 to 12.79    .417        −2.28   −10.50 to 5.94   .647
  Surgery                                                                                       
   (ref = no surgery)           4.66     −4.56 to 13.89    .392        4.64    −4.00 to 13.28   .364
  Tear size (large/massive)                                                                     
   (ref = small/medium)         2.01     −6.63 to 10.65    .691        −3.66   −11.67 to 4.35   .439
  Side                                                                                          
   (ref = left)                 −2.06    −10.83 to 6.71    .688        0.18    −8.09 to 8.46    .970
  Diabetes                                                                                      
   (ref = no diabetes)          −9.37    −20.84 to 2.10    .174        11.73   1.44 to 22.02    .064^*c*^
  Smoking                                                                                       
   (ref = no smoking)           4.45     −6.19 to 15.09    .477        −4.83   −14.77 to 5.11   .410
  Symptom duration (\>1 year)                                                                   
   (ref = \<1 year)             −9.71    −17.42 to −1.99   .043^*c*^   1.59    −6.53 to 9.71    .738

^*a*^BMI, body mass index; CCI, Charlson Comorbidity Index; MCS, mental component score; MID, minimal clinical difference; PCS, physical component score; ref, reference; VR-12, Veterans RAND 12-Item Health Survey.

^*b*^ *P* \< .05.

^*c*^ *P* \< .1.

###### 

Simple Linear Regression Analyses for SANE Anchor-Based MID*^a^*

![](10.1177_2325967118782159-table4)

  Covariate                     β        90% CI            *P* Value
  ----------------------------- -------- ----------------- -----------
  Age                           0.56     −0.63 to 1.74     .425
  BMI                           0.66     −1.45 to 2.77     .595
  Baseline SANE                 −0.71    −1.36 to −0.06    .073^*b*^
  CCI                           16.95    −6.95 to 40.66    .230
  Sex                                                      
   (ref = female)               −3.93    −28.78 to 20.93   .787
  Injection                                                
   (ref = no injection)         9.17     −13.83 to 32.16   .498
  Surgery                                                  
   (ref = no surgery)           5.12     −19.70 to 29.94   .725
  Tear size (large/massive)                                
   (ref = small/medium)         17.12    −4.73 to 38.97    .191
  Side                                                     
   (ref = left)                 3.13     −20.14 to 26.39   .818
  Diabetes                                                 
   (ref = no diabetes)          −33.24   −62.17 to −4.30   .062^*b*^
  Smoking                                                  
   (ref = no smoking)           −3.44    −31.94 to 25.06   .837
  Symptom duration (\>1 year)                              
   (ref = \<1 year)             −15.00   −37.11 to 7.11    .255

^*a*^BMI, body mass index; CCI, Charlson Comorbidity Index; MID, minimal clinical difference; ref, reference; SANE, Single Assessment Numeric Evaluation.

^*b*^ *P* \< .1.

From the results of simple linear regressions on the PCS, we started the backward selection modeling with the following variables: baseline PCS, diabetes, symptom duration, BMI, CCI, and surgery. The final model predicting the MID for PCS consisted of 5 significant predictors: baseline PCS, BMI, symptom duration, diabetes, and surgery ([Table 5](#table5-2325967118782159){ref-type="table"}). The results of regression analyses showed that when adjusted for all of the other covariates, the MID of PCS decreased by β for every unit increase in BMI, baseline PCS, presence of diabetes, and symptoms longer than 1 year and increased for patients receiving surgery.

###### 

Final Model for VR-12 PCS Anchor-Based MID (*R* ^2^ = 0.80)^*a*^

![](10.1177_2325967118782159-table5)

  Covariate                     β        90% CI            *P* Value
  ----------------------------- -------- ----------------- -----------
  BMI                           −0.73    −1.18 to −0.27    .014
  Baseline PCS                  −0.59    −0.80 to −0.38    \<.001
  Diabetes                                                 
   (ref = no diabetes)          −10.96   −17.32 to −4.60   .009
  Symptom duration (\>1 year)                              
   (ref = \<1 year)             −7.81    −12.49 to −3.13   .011
  Surgery                                                  
   (ref = no surgery)           5.22     0.19 to 10.25     .089

*^a^*BMI, body mass index; MID, minimal clinical difference; PCS, physical component score; ref, reference; VR-12, Veterans RAND 12-Item Health Survey.

The backward selection modeling for the MID of MCS was begun with the following variables: baseline MCS score, sex, diabetes, surgery, age, and smoking. The final model for the MID of MCS included baseline MCS score, sex, and diabetes ([Table 6](#table6-2325967118782159){ref-type="table"}). In the final multivariable model, the MID of MCS in the cohort of patients with RCT decreased with higher baseline MCS and was increased in male patients and in patients with diabetes.

###### 

Final Model for VR-12 MCS Anchor-Based MID (*R* ^2^ = 0.67)^*a*^
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  Covariate              β       90% CI           *P* Value
  ---------------------- ------- ---------------- -----------
  Baseline MCS           −0.55   −0.78 to −0.32   \<.001
  Sex                                             
   (ref = female)        7.89    2.25 to 13.53    .027
  Diabetes                                        
   (ref = no diabetes)   7.68    0.43 to 14.93    .083

*^a^*MCS, mental component score; MID, minimal clinical difference; ref, reference; VR-12, Veterans RAND 12-Item Health Survey.

For the MID of the SANE score, after backward selection was performed, the MID decreased with higher baseline SANE scores and in patients with diabetes ([Table 7](#table7-2325967118782159){ref-type="table"}).

###### 

Final Model for SANE Anchor-Based MID (*R* ^2^ = 0.34)*^a^*

![](10.1177_2325967118782159-table7)

  Covariate              β        90% CI            *P* Value
  ---------------------- -------- ----------------- -----------
  Baseline SANE          −0.69    −1.29 to −0.10    .059
  Diabetes                                          
   (ref = no diabetes)   −32.51   −59.33 to −5.70   .050

*^a^*MID, minimal clinical difference; ref, reference; SANE, Single Assessment Numeric Evaluation.

Discussion {#section13-2325967118782159}
==========

PROM questionnaires are widely used in evidence-based medicine to bring patients' opinions into the decision-making process. However, without a proper interpretation of the numbers, the results of PROMs are of little value in making decisions about treatments.^[@bibr12-2325967118782159]^ To determine how much of a change in a PROM matters to patients, we need to explore the MIDs of PROMs for different populations.

The current study aimed to calculate the MID for the VR-12 score and the SANE rating in patients with RCT and to identify important predictors of the MIDs. We had several reasons for selecting the VR-12 and SANE for the current study. First, both of them are simplified, validated, and widely used PROMs. The SANE score is single-item and the VR-12 has only 12 items. Using these PROMs helps relieve the burden for both the respondent and the clinician, considering the total amount of information needed in clinical research. Second, since VR-12 summarizes different health domains into physical and mental component scores, it allows us to make comparisons between the changes in patients' physical and mental health status. At the same time, the SANE score assesses the functional change of the patients. By combining the results of those 2 PROMs, we were able to provide an assessment of patients' perceived changes on both overall health status and shoulder function.

From the results of our study, we found that the MIDs generated from the anchor-based approach were smaller than those generated from the distribution-based approach, with 1 exception: the anchor-based MID for the SANE rating was much higher than the distribution-based MID. This latter finding could be due to the relatively high amount of variability of the SANE ratings in our study sample. Because the SANE measures shoulder function, it may be more sensitive to the differences in the severity of RCT among patients. However, the VR-12 is a measure of health quality of life, which may not be as strongly related to RCT severity and symptoms as the SANE rating.

As far as we know, there are few published studies about the MID of the VR-12 or the SANE score.^[@bibr13-2325967118782159],[@bibr24-2325967118782159]^ None of the available studies used a population of patients with RCT or investigated the associations between patients' baseline characteristics and the MID.

Kronzer et al^[@bibr13-2325967118782159]^ estimated the VR-12 MID for patients undergoing elective surgery. Their anchor-based MID values for PCS and MCS were 4 and 6.5, respectively, which are much higher than the anchor-based MID estimations of our study. However, the methods used in the study by Kronzer et al^[@bibr13-2325967118782159]^ are questionable. In the global assessment, they asked patients to rate their quality of life as "better," "same," or "worse" without specifying the magnitude of change. Their anchor-based MIDs were computed using the VR-12 score of all the patients who reported a "better" quality of life. The results were the mean change in scores for all the patients who perceived an improvement. Thus, the MID estimations were not an indicator of minimal important improvement and are likely to be much higher than the true value.

In our study, we were able to identify a group of patients with minimal important improvement from all patients who perceived an improvement. Therefore, our MID estimations can represent the minimal change of the PROM score for those patients with improved health. In other words, those estimates can be used as a threshold of patients' perceived health improvement.

The MIDs for the VR-12 were similar to the MID of the SF-36 reported in previous studies,^[@bibr5-2325967118782159],[@bibr25-2325967118782159]^ in which the MID for PCS ranged from 1.6 to 7.0 and the MID for MCS ranged from 2.3 to 8.7. The small differences between our study and other studies could be caused by the differences in the characteristics of study samples and the approaches toward estimating MID.

In terms of the SANE score, Winterstein et al^[@bibr24-2325967118782159]^ reported MIDs of 7 for a 6-month follow-up and 19 for a 12-month follow-up, which are lower than our estimate. However, since our study has a longer follow-up period, 64 weeks (16 months), it is reasonable for the patients to have a higher MID.

Using the same patient cohort as our study, Gagnier et al^[@bibr8-2325967118782159]^ established the MIDs for the American Shoulder and Elbow Surgeons (ASES) score and the Western Ontario Rotator Cuff Index (WORC). That study used similar distribution- and anchor-based approaches to the current study and also found differences in the MIDs estimated from the 2 types of approaches. However, in the regression analysis, Gagnier et al^[@bibr8-2325967118782159]^ included only age, sex, and CCI score as independent variables and did not find any statistically significant associations between these variables and the MID. In our study, we also found that age or CCI score did not predict the MID, except that sex was associated with the MID of the MCS. However, the WORC and ASES mostly measure physical health, and only 3 among the 21 items in the WORC are about emotional function. Therefore, in terms of mental health, WORC and ASES scores are not comparable with the results of the MCS. Gagnier et al^[@bibr8-2325967118782159]^ reported similar results on MIDs for physical health outcome measures compared with our study. Because they did not include other demographic variables, such as diabetes and BMI, which were found in our study to be significant predictors of MID, we were unable to compare the results and will require future studies to confirm our findings.

According to the results of the paired *t* tests, for the patients in the minimal change group, the 64-week MCS and PCS scores were not statistically significantly different from the baseline scores. This indicates that even if a change in VR-12 score is not statistically significant, it might still be perceived by the patients and might be of clinical importance for the evaluation of treatment. In addition, because statistical significance is largely influenced by sample size, the nonsignificant *P* value might be related to the small sample size of the minimal improvement group. It is possible that future studies with a much larger sample size would detect a statistically significant MID for the VR-12. In terms of the paired *t* test on the SANE score, the *P* value was less than .001, which indicates that the anchor-based MID for the SANE rating is statistically significant. Given that the primary objectives of treatment for RCT are to relieve pain, restore shoulder function, and improve quality of life, which are mostly subjective, perceived changes are of greater direct importance to patients than statistically significant changes. Therefore, the MID estimates can aid in the interpretation of clinical relevance of the PROMs, and more studies are needed to validate the current results.

In the final model obtained after backward model selections, the baseline PCS, MCS, and SANE scores were negatively associated with the corresponding MIDs. Previous studies also observed negative associations between baseline scores and MIDs.^[@bibr2-2325967118782159],[@bibr7-2325967118782159]^ Therefore, the baseline score can be used as a reliable predictor for the VR-12 and SANE MIDs at 64 weeks in the treatment and rehabilitation of patients with RCT. The negative associations indicate that patients with a higher baseline score perceived a smaller change in their quality of life and shoulder function as meaningful. The reason for these negative associations might be related to the higher levels of sensitivity to change in physical and mental health status and shoulder functioning in patients with a better general condition at baseline.

The final model also suggested that a higher BMI was associated with a lower PCS MID at 64 weeks, which indicates that the patients with RCT who had a higher BMI considered a smaller change in their PCS as meaningful after receiving treatments. In addition, patients who had surgery had a higher MID for PCS compared with those who did not. This suggests that patients who have surgery might have a higher expectation for improvement. Therefore, they consider a larger change in their physical health as minimally important. A sex-based difference in MCS MID was observed, and male patients had a much higher MID compared with female patients when we controlled for baseline score and diabetes. This result suggests that female patients with RCT considered a smaller change in their mental status as significant compared with male patients after receiving treatment. However, similar results were not observed in MID for PCS. This might be due to the different underlying factors and mechanisms that influence mental health status and physical health status.

A surprising finding of the multivariable analyses was that patients with diabetes had lower PCS MID and SANE MID but a higher MCS MID, compared with those without diabetes, on average. This means that patients with diabetes perceived a smaller change in their physical health, indicated by the PCS and SANE, as meaningful and a larger change in MCS as meaningful. Based on the β coefficients, the magnitudes of the negative associations between diabetes and the MIDs of the PCS and SANE were stronger than the positive association between diabetes and the MCS. A previous study suggested that self-rated mental health was not related to chronic physical conditions, while self-rated physical health was strongly related to chronic physical conditions.^[@bibr14-2325967118782159]^ This could explain the difference in the magnitudes of the associations.

The current study provides a range of possible MIDs for the VR-12 and SANE, estimated by use of anchor-based and distribution-based approaches. Although the anchor-based MIDs are considered to be more clinically relevant, the small sample size used in the analysis limited the precision of our estimates. Therefore, future studies with a larger sample size are needed to systematically evaluate and determine the MID of the VR-12 and SANE for patients with RCT.

Despite limitations posed by the small sample size, we established models to predict the MID for the VR-12 and SANE based on a patient's baseline characteristics. Using these models, clinicians can predict which patients have a smaller MID and are therefore more likely to achieve a clinically important improvement in their mental and physical health after receiving treatments.

This study has several strengths. First, to our knowledge, it is the first to estimate MID for the VR-12 and SANE in patients with shoulder disorders. Second, we used both distribution-based and anchor-based approaches to compute the MID, which is a recommended method to estimate MID.^[@bibr21-2325967118782159]^ Third, we conducted regression analysis on MID using patients' characteristics and the treatments as predictors and built models for prediction of MID on the VR-12 and the SANE. Our results can be used to facilitate future studies and inform decision making in clinical practices. For example, at the individual level, the MID can be used as a threshold to inform the clinician regarding how much change in the VR-12 or the SANE score is sufficient to warrant a change in the treatment. At the group level, the MID estimates can be used to decide whether the difference between the 2 treatments is clinically significant.

Our study also has some limitations. First, the results of the global change questionnaire are susceptible to recall bias, which could have biased our study findings.^[@bibr15-2325967118782159]^ Second, the minimal important change group had only 20 patients, which may limit our statistical power, but we were careful to choose only a small number of variables in our regression modeling to minimize type I errors. Third, we used a global self-perceived health rating as the anchor for clinically significant improvements, which is of course, highly subjective.

Conclusion {#section14-2325967118782159}
==========

This is the first study to establish the MID of VR-12 and SANE scores in patients with RCTs. We found that several variables, including baseline scores, BMI, sex, diabetes, symptom duration, and surgery, predicted variations in the MID. Future studies with larger sample sizes, stratified by these variables, are needed to further explore the results of the current study.
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